ORBIMED ADVISORS LLC Q2 2024 Filing
Filed August 14, 2024
Portfolio Value
$5.1B
Holdings
110
Report Date
Q2 2024
Filing Type
13F-HR
All Holdings (110 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | CMMBCHEMOMAB THERAPEUTICS LTD | 2,241,273 | $2.0B | 40.38% | |
| 102 | ORICORIC PHARMACEUTICALS INC | 287,100 | $2.0B | 40.08% | |
| 103 | NXTCNEXTCURE INC | 1,141,200 | $1.8B | 35.83% | |
| 104 | APLMAPOLLOMICS INC | 8,565,456 | $1.8B | 35.67% | |
| 105 | VIGLVIGIL NEUROSCIENCE INC | 448,891 | $1.8B | 35.45% | |
| 106 | DVAXDYNAVAX TECHNOLOGIES CORP | 113,500 | $1.3B | 25.17% | |
| 107 | KZRKEZAR LIFE SCIENCES INC | 1,927,000 | $1.2B | 22.83% | |
| 108 | —LAKESHORE BIOPHARMA CO LTD | 1,404,280 | $909.8M | 17.96% | |
| 109 | ONTXUSDTRAWS PHARMA INC | 1,045,261 | $466.9M | 9.22% | |
| 110 | XERSXERIS BIOPHARMA HOLDINGS INC | 80,420 | $180.9M | 3.57% | |
| 111 | —SINGULAR GENOMICS SYSTEMS IN | 18,023 | $152.3M | 3.01% |
PreviousPage 2 of 2